Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  lenalidomide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 267 for your search:
Start Over
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 07-134, NCT00777881
Phase II/III Randomized Study of CC-5013 in Patients With Progressive or Relapsed Metastatic Malignant Melanoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0210051, CELGENE-CDC-501-MEL-001, MSKCC-03026, NCT00060281
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase: Phase III, Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00242, SWOG-S1117, CDR0000723909, S1117, U10CA180888, U10CA032102, NCT01522976
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0232, U10CA032102, SWOG-S0232, NCT00064038
Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MEL-002, NCT00057616
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2003-35, NCT00093028
Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: NCI-2009-00439, CDR0000434845, CALGB 100104/ECOG 100104, CALGB-100104, U10CA031946, P30CA014236, ECOG-CALGB-100104, NCT00114101
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MDS-004, 2005-000454-73, NCT00179621
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-015, 2006-001865-41, NCT00405756
Maintenance Therapy Using Lenalidomide in Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 0400401, French PHRC, NCT00430365
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-018, 2006-002517-12, NCT00420849
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-000649-36, QUIREDEX, NCT00480363
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00521, CDR0000561758, ECOG-E1A05, E1A05, U10CA021115, U10CA180820, NCT00522392
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: RV-MM-PI-209, NCT00551928
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00522, CDR0000583984, ECOG-E1A06, E1A06, U10CA180820, U10CA021115, NCT00602641
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00798, SWOG-S0777, CDR0000590321, S0777, U10CA032102, U10CA180888, NCT00644228
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-020, 2007-004823-39, NCT00689936
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-009, NCT00056160
A Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-010, NCT00424047
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and ovr
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-008, 2008-003079-32, NCT00910910
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Subjects With Previously Treated Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-022, NCT00928486
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03150, CDR0000404161, E4A03, U10CA021115, U10CA180820, ECOG-E4A03, NCT00098475
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-PC-002, EudraCT Number 2008-007969-23, NCT00988208
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Phase: Phase III
Type: Health services research, Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MDS-005, NCT01029262
Start Over